|
|
Blood, 1 November 2004, Vol. 104, No. 9, pp. 2919-2925.
Prepublished online as a Blood First Edition Paper on July 8, 2004; DOI 10.1182/blood-2004-03-0901.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Characterization of acute lymphoblastic leukemia progenitor cells
Charlotte V. Cox,
Roger S. Evely,
Anthony Oakhill,
Derwood H. Pamphilon,
Nicholas J. Goulden, and
Allison Blair
From Bristol Institute for Transfusion Sciences, United Kingdom; Bristol Haematology and Oncology Centre, United Kingdom; Bristol Royal Hospital for Children, United Kingdom; and Department of Pathology and Microbiology, University of Bristol, United Kingdom.
Only some acute lymphoblastic leukemia (ALL) cells are thought to be capable of proliferating to maintain the leukemic clone, and these cells may be the most relevant to target with treatment regimens. We have developed a serum-free suspension culture (SC) system that supported growth of B-ALL cells from 33 patients for up to 6 weeks. ALL cells from 28 cases (85%) were expanded in this system, and growth was superior in SC than in long-term bone marrow culture. To characterize ALL progenitors, cells were sorted for expression of CD34 and CD10 or CD19 and the subfractions assayed in SC and in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice. Cells capable of long-term proliferation in vitro and NOD/SCID repopulation were derived only from the CD34+/CD10- and CD34+/CD19- subfractions, and these cells could engraft secondary recipients. The engrafted cells had the same immunophenotype and karyotype as was seen at diagnosis, suggesting they had differentiated in vivo. These results demonstrate that ALL cells capable of long-term proliferation in vitro and in vivo are CD34+/CD10-/CD19-. This suggests that cells with a more immature phenotype, rather than committed B-lymphoid cells, may be the targets for transformation in B-ALL.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Letter in Blood Online:
-
Growth requirements and immunophenotype of acute lymphoblastic leukemia progenitors
- Dario Campana, Shotaro Iwamoto, Linda Bendall, and Kenneth Bradstock
Blood 2005 105: 4150.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
E. Kavalerchik, D. Goff, and C. H.M. Jamieson
Chronic Myeloid Leukemia Stem Cells
J. Clin. Oncol.,
June 10, 2008;
26(17):
2911 - 2915.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Hong, R. Gupta, P. Ancliff, A. Atzberger, J. Brown, S. Soneji, J. Green, S. Colman, W. Piacibello, V. Buckle, et al.
Initiating and Cancer-Propagating Cells in TEL-AML1-Associated Childhood Leukemia
Science,
January 18, 2008;
319(5861):
336 - 339.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Guzman, X. Li, C. A. Corbett, R. M. Rossi, T. Bushnell, J. L. Liesveld, J. Hebert, F. Young, and C. T. Jordan
Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8)
Blood,
December 15, 2007;
110(13):
4436 - 4444.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Guzman, R. M. Rossi, S. Neelakantan, X. Li, C. A. Corbett, D. C. Hassane, M. W. Becker, J. M. Bennett, E. Sullivan, J. L. Lachowicz, et al.
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells
Blood,
December 15, 2007;
110(13):
4427 - 4435.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Wang, H. O'Leary, J. Fortney, and L. F. Gibson
Ph+/VE-cadherin+ identifies a stem cell like population of acute lymphoblastic leukemia sustained by bone marrow niche cells
Blood,
November 1, 2007;
110(9):
3334 - 3344.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Juarez, R. Baraz, S. Gaundar, K. Bradstock, and L. Bendall
Interaction of interleukin-7 and interleukin-3 with the CXCL12-induced proliferation of B-cell progenitor acute lymphoblastic leukemia
Haematologica,
April 1, 2007;
92(4):
450 - 459.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. V. Cox, H. M. Martin, P. R. Kearns, P. Virgo, R. S. Evely, and A. Blair
Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia
Blood,
January 15, 2007;
109(2):
674 - 682.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. T. Jordan, M. L. Guzman, and M. Noble
Cancer stem cells.
N. Engl. J. Med.,
September 21, 2006;
355(12):
1253 - 1261.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Serrano, T. Pfeiffer, S. Olivares, T. Numbenjapon, J. Bennitt, D. Kim, D. Smith, G. McNamara, Z. Al-Kadhimi, J. Rosenthal, et al.
Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy
Blood,
April 1, 2006;
107(7):
2643 - 2652.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Yuan, H. Yu, M. J. Boyer, X. Song, S. Cao, H. Shen, and T. Cheng
Hematopoietic Stem Cells Are Not the Direct Target of Spontaneous Leukemic Transformation in p18INK4C-Null Reconstituted Mice
Cancer Res.,
January 1, 2006;
66(1):
343 - 351.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. DICK
Proceedings of the International Conference and Workshop on Hematopoietic Stem Cells V. September 16-18, 2004, Tubingen, Germany.
Ann. N.Y. Acad. Sci.,
June 1, 2005;
1044:
1 - 243.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Campana, S. Iwamoto, L. Bendall, and K. Bradstock
Growth requirements and immunophenotype of acute lymphoblastic leukemia progenitors
Blood,
May 15, 2005;
105(10):
4150 - 4150.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hotfilder, S. Rottgers, A. Rosemann, A. Schrauder, M. Schrappe, R. Pieters, H. Jurgens, J. Harbott, and J. Vormoor
Leukemic Stem Cells in Childhood High-Risk ALL/t(9;22) and t(4;11) Are Present in Primitive Lymphoid-Restricted CD34+CD19- Cells
Cancer Res.,
February 15, 2005;
65(4):
1442 - 1449.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
